Experimental cocktail aims to beat back tough leukemia

NCT ID NCT05029141

Ongoing Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of chidamide, azacytidine, and a chemotherapy regimen (HAG) in 21 adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see how well the combo works and what side effects it causes. Participants receive two 28-day cycles of the drug regimen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chidamide, azacytidine, cytarabine, homoharringtonine, and granulocyte colony-stimulating factor
What this could lead to: If successful, this combination could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong: This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drugs can cause serious side effects like low blood counts and infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE LEUKEMIA RELAPSED ADULT AML

Contacts and locations

Locations

The First Affliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.